Stock Scorecard

Stock Summary for Revolution Medicines Inc (RVMD) - $39.05 as of 7/18/2025 3:32:56 PM EST

Total Score

6 out of 30

Safety Score

39 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for RVMD

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for RVMD

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for RVMD

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for RVMD

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for RVMD (39 out of 100)

Stock Price Rating (Max of 10) 8
Historical Stock Price Rating (Max of 10) 7
Stock Price Trend (Max of 10) 9
Book Value (Max of 10) 5
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 0
Analyst Strong Buy Ratings (Max of 5) 0
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 10
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for RVMD

This GitLab Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - GitLab ( NASDAQ:GTLB ) , Amrize ( NYSE:AMRZ ) 7/15/2025 12:34:00 PM
Revolution Medicines and Iambic Announce Technology and Research Collaboration Using Iambic's AI Discovery Tools to Pursue New Drug Candidates 7/9/2025 12:00:00 PM
Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS ( ON ) Inhibitors with Ivonescimab in RAS Mutant Tumors - Summit Therapeutics ( NASDAQ:SMMT ) , Revolution Medicines ( NASDAQ:RVMD ) 6/30/2025 12:00:00 PM
Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS ( ON ) Inhibitors with Ivonescimab in RAS Mutant Tumors 6/30/2025 12:00:00 PM
Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines' Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung Cancer 6/27/2025 11:00:00 AM
Revolution Medicines To Advance Lead Cancer Drug With Funding Worth $2B - Royalty Pharma ( NASDAQ:RPRX ) , Revolution Medicines ( NASDAQ:RVMD ) 6/24/2025 6:35:00 PM
Royalty Pharma and Revolution Medicines Enter Into Funding Agreements for Up to $2 Billion 6/24/2025 11:05:00 AM
Royalty Pharma and Revolution Medicines Enter Into Funding Agreements for Up to $2 Billion - Royalty Pharma ( NASDAQ:RPRX ) 6/24/2025 11:05:00 AM
Revolution Medicines Enters Into $2 Billion Flexible Funding Agreement with Royalty Pharma to Support Global Development and Commercialization of RAS ( ON ) Inhibitor Portfolio for Patients with RAS-Addicted Cancers - Revolution Medicines ( NASDAQ:RVMD ) 6/24/2025 11:00:00 AM
Revolution Medicines Announces FDA Breakthrough Therapy Designation for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer with KRAS G12 Mutations 6/23/2025 1:00:00 PM

Financial Details for RVMD

Company Overview
Ticker RVMD
Company Name Revolution Medicines Inc
Country USA
Description Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Sector Name LIFE SCIENCES
Industry Name BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Most Recent Quarter 3/31/2025
Next Earnings Date 8/6/2025

Stock Price History
Last Day Price 39.05
Price 4 Years Ago 25.17
Last Day Price Updated 7/18/2025 3:32:56 PM EST
Last Day Volume 2,141,511
Average Daily Volume 2,612,996
52-Week High 62.40
52-Week Low 29.17
Last Price to 52 Week Low 33.87%

Valuation Measures
Trailing PE N/A
Industry PE 56.18
Sector PE 40.31
5-Year Average PE -13.99
Free Cash Flow Ratio 21.82
Industry Free Cash Flow Ratio 19.90
Sector Free Cash Flow Ratio 32.27
Current Ratio Most Recent Quarter 13.46
Total Cash Per Share 1.79
Book Value Per Share Most Recent Quarter 11.16
Price to Book Ratio 3.39
Industry Price to Book Ratio 19.01
Sector Price to Book Ratio 30.89
Price to Sales Ratio Twelve Trailing Months 9,035.10
Industry Price to Sales Ratio Twelve Trailing Months 48.49
Sector Price to Sales Ratio Twelve Trailing Months 38.93
Analyst Buy Ratings N/A
Analyst Strong Buy Ratings N/A

Share Statistics
Total Shares Outstanding 186,268,000
Market Capitalization 7,273,765,400
Institutional Ownership 105.97%

Dividends
Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement
Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -37.52%
Reported EPS 12 Trailing Months -4.01
Reported EPS Past Year -1.13
Reported EPS Prior Year -3.57
Net Income Twelve Trailing Months -697,506,000
Net Income Past Year -600,093,000
Net Income Prior Year -436,367,000
Quarterly Revenue Growth YOY -95.20%
5-Year Revenue Growth -100.00%
Operating Margin Twelve Trailing Months 0.00%

Balance Sheet
Total Cash Most Recent Quarter 333,554,000
Total Cash Past Year 543,064,000
Total Cash Prior Year 696,148,000
Net Cash Position Most Recent Quarter 333,554,000
Net Cash Position Past Year 543,064,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 2,265,204,000
Total Stockholder Equity Prior Year 1,826,194,000
Total Stockholder Equity Most Recent Quarter 2,078,150,000

Free Cash Flow
Free Cash Flow Twelve Trailing Months -601,718,000
Free Cash Flow Per Share Twelve Trailing Months -3.23
Free Cash Flow Past Year -567,744,000
Free Cash Flow Prior Year -358,301,000

Options
Put/Call Ratio 1.54
Has Options Options Chain
Liquidity Rating

Technical Analysis
Yahoo Finance Chart Yahoo Finance Chart
MACD -0.29
MACD Signal -0.42
20-Day Bollinger Lower Band 34.16
20-Day Bollinger Middle Band 38.47
20-Day Bollinger Upper Band 42.78
Beta 1.10
RSI 49.04
50-Day SMA 43.06
150-Day SMA 32.79
200-Day SMA 30.44

System
Modified 7/19/2025 9:23:05 AM EST